RESUMO
HLA-A*24:617 differs from HLA-A*24:02:01:01 by one nucleotide in exon 4.
Assuntos
Alelos , Povo Asiático , Sequência de Bases , Éxons , Antígeno HLA-A24 , Teste de Histocompatibilidade , Análise de Sequência de DNA , Humanos , Antígeno HLA-A24/genética , Povo Asiático/genética , Análise de Sequência de DNA/métodos , Alinhamento de Sequência , Códon , Polimorfismo de Nucleotídeo Único , População do Leste AsiáticoRESUMO
HLA-A*02:1146 differs from HLA-A*02:01:01:01 by one nucleotide in exon 1.
Assuntos
Alelos , Povo Asiático , Sequência de Bases , Éxons , Antígeno HLA-A2 , Teste de Histocompatibilidade , Análise de Sequência de DNA , Humanos , Povo Asiático/genética , Análise de Sequência de DNA/métodos , Antígeno HLA-A2/genética , Alinhamento de Sequência , Códon , População do Leste AsiáticoRESUMO
HLA-C*07:1089 differs from HLA-C*07:02:01:01 by one nucleotide in exon 3.
Assuntos
Éxons , Antígenos HLA-C , Teste de Histocompatibilidade , Humanos , Alelos , Sequência de Bases , Códon , População do Leste Asiático , Antígenos HLA-C/genética , Alinhamento de Sequência , Análise de Sequência de DNA/métodosRESUMO
HLA-A*11:01:127 differs from HLA-A*11:01:01:01 by one nucleotide in exon 3.
Assuntos
Alelos , Povo Asiático , Sequência de Bases , Éxons , Antígeno HLA-A11 , Teste de Histocompatibilidade , Análise de Sequência de DNA , Humanos , Povo Asiático/genética , Análise de Sequência de DNA/métodos , Antígeno HLA-A11/genética , Códon , Alinhamento de Sequência , População do Leste AsiáticoRESUMO
HLA-B*15:02:15 differs from HLA-B*15:02:01:01 by one nucleotide in exon 2.
Assuntos
Éxons , Antígeno HLA-B15 , Teste de Histocompatibilidade , Humanos , Alelos , Sequência de Bases , Códon , População do Leste Asiático , Antígeno HLA-B15/genética , Antígeno HLA-B15/imunologia , Alinhamento de Sequência , Análise de Sequência de DNA/métodosRESUMO
HLA-C*14:155 differs from HLA-C*14:02:01:01 by one nucleotide in exon 1.
Assuntos
Alelos , Povo Asiático , Sequência de Bases , Éxons , Antígenos HLA-C , Teste de Histocompatibilidade , Análise de Sequência de DNA , Humanos , Antígenos HLA-C/genética , Povo Asiático/genética , Análise de Sequência de DNA/métodos , Alinhamento de Sequência , Códon , População do Leste AsiáticoRESUMO
Several genes involved in the pathogenesis have been identified, with the human leukocyte antigen (HLA) system playing an essential role. However, the relationship between HLA and a cluster of hematological diseases has received little attention in China. Blood samples (n = 123913) from 43568 patients and 80345 individuals without known pathology were genotyped for HLA class I and II using sequencing-based typing. We discovered that HLA-A*11:01, B*40:01, C*01:02, DQB1*03:01, and DRB1*09:01 were prevalent in China. Furthermore, three high-frequency alleles (DQB1*03:01, DQB1*06:02, and DRB1*15:01) were found to be hazardous in malignant hematologic diseases when compared to controls. In addition, for benign hematologic disorders, 7 high-frequency risk alleles (A*01:01, B*46:01, C*01:02, DQB1*03:03, DQB1*05:02, DRB1*09:01, and DRB1*14:54) and 8 high-frequency susceptible genotypes (A*11:01-A*11:01, B*46:01-B*58:01, B*46:01-B*46:01, C*01:02-C*03:04, DQB1*03:01-DQB1*05:02, DQB1*03:03-DQB1*06:01, DRB1*09:01-DRB1*15:01, and DRB1*14:54-DRB1*15:01) were observed. To summarize, our findings indicate the association between HLA alleles/genotypes and a variety of hematological disorders, which is critical for disease surveillance.
Assuntos
Doenças Hematológicas , Antígenos de Histocompatibilidade Classe I , Humanos , Frequência do Gene , Alelos , Cadeias beta de HLA-DQ/genética , Cadeias HLA-DRB1/genética , Genótipo , Antígenos de Histocompatibilidade Classe I/genética , Doenças Hematológicas/genética , Haplótipos , Predisposição Genética para DoençaRESUMO
HLA-DPB1*1550:01 differs from HLA-DPB1*02:02:01:01 by one nucleotide in exon 2.
Assuntos
Cadeias beta de HLA-DP , Nucleotídeos , Humanos , Alelos , Sequência de Bases , ChinaRESUMO
HLA-DPB1*03:01:29 differs from HLA-DPB1*03:01:01:01 by one nucleotide in exon 2.
Assuntos
Cadeias beta de HLA-DP , Nucleotídeos , Humanos , Alelos , Análise de Sequência de DNA , ChinaRESUMO
HLA-C*12:02:52 differs from HLA-C*12:02:02:01 by one nucleotide in exon 1.
Assuntos
Genes MHC Classe I , Antígenos HLA-C , Humanos , Antígenos HLA-C/genética , Alelos , Nucleotídeos , China , Análise de Sequência de DNARESUMO
HLA-B*58:144N differs from HLA-B*58:01:01:01 by one nucleotide in exon 2.
Assuntos
Antígenos HLA-B , Nucleotídeos , Humanos , Alelos , Análise de Sequência de DNA , Antígenos HLA-B/genética , ChinaRESUMO
HLA-C*01:255 differs from HLA-C*01:02:01:01 by one nucleotide in exon 2.
Assuntos
Antígenos HLA-C , Nucleotídeos , Humanos , Antígenos HLA-C/genética , Alelos , Sequência de Bases , China , Análise de Sequência de DNARESUMO
OBJECTIVE: To establish a new digital polymerase chain reaction (dPCR) system for the detection of BCR-ABL fusion gene in patients with chronic myeloid leukemia (CML), and explore its analytical performance and clinical applicability in the detection of BCR-ABLp190/210/230. METHODS: A new dPCR system for detecting BCR-ABLp190/210/230 was successfully developed, and its sensitivity difference with qPCR and improvement of drug side effects in patients with CML during drug reduction or withdrawal were compared. RESULTS: Among 176 samples, qPCR and dPCR showed high consistency in the sensitivity of detecting BCR-ABL (82.39%), and the positive rate of dPCR was about 5 times higher that of qPCR (20.45% vs 3.98%). During follow-up, blood routine (25% vs 10%), kidney/liver/stomach (25% vs 20%) and cardiac function (10% vs 0) were significantly improved after drug reduction or withdrawal in patients with initial dPCR negative compared with before drug reduction or withdrawal. CONCLUSIONS: This new dPCR detection system can be applied to the detection of BCR-ABLp190/210/230. It has better consistency and higher positive detection rate than qPCR. Drug withdrawal or dose reduction guided by dPCR has a certain effect on improving drug side effects.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Leucemia Mielogênica Crônica BCR-ABL Positiva , Humanos , Proteínas de Fusão bcr-abl/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/diagnóstico , Reação em Cadeia da Polimerase , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
The function of natural killer (NK) cells has previously been implicated in hematopoietic-related diseases. Killer immunoglobulin-like receptors (KIR) play an important role in NK cells after hematopoietic stem cell transplantation. To explore the immunogenetic predisposition of hematological-related diseases, herein, a multi-center retrospective study in China was conducted, analyzing and comparing 2519 patients with hematopathy (mainly, acute lymphoblastic leukemia, acute myeloid leukemia, aplastic anemia, and myelodysplastic syndrome) to 18,108 individuals without known pathology. Genotyping was performed by polymerase chain reaction with specific sequence primers (PCR-SSP). As a result, we discovered four genes including KIR2DL5 (OR: 0.74, 95% CI 0.59-0.93; Pc = 0.0405), 2DS1 (OR: 0.74, 95% CI 0.59-0.93; Pc = 0.0405), 2DS3 (OR: 0.58, 95% CI 0.41-0.81; Pc = 0.0180), and 3DS1 (OR: 0.74, 95% CI 0.58-0.94; Pc = 0.0405) to be protective factors that significantly reduce the risk of aplastic anemia. Our findings offer new approaches to immunotherapy for hematological-related diseases. As these therapies mature, they are promising to be used alone or in combination with current treatments to help to make blood disorders a manageable disease.